Apart from supply of ARV issue, other triggers to defaulting on treatment include integration of HIV services in outpatient units. Majority of the 41,547 Kenyans who had been employed under the ...

Arvinas, Inc, a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, announced that new preclinical combination data for ARV-393 will be ...